From 2000-2007, Mike Cleare was the Executive Director of Science and Technology Ventures at Columbia University. In August 2007, Cleare joined the University of Pennsylvania as Associate Vice Provost for Research, responsible for all technology transfer, IP management and industrial liaison activities. He retired in 2013 having enabled the successful creation of the Penn Centre for Innovation (PCI) covering all knowledge transfer, industrial funding and entrepreneurial activities including incubation of company start-ups based on Penn’s technologies.
Cleare worked for 30 years at Johnson Matthey, a UK-based multinational world leader in advanced materials technology While in R&D, Cleare was involved in the discovery and development of a major new class of anti-cancer drugs (platinum based-particularly carboplatin). He served as President of several of the company's major divisions, including Pharmaceutical Materials, Chemicals and Metals, Catalytic Systems and Electronic Materials. He has managed complex global business, negotiated and closed multi-million-dollar licensing and technology transfer deals, and entered into multiple research funding agreements with major universities.
For nine years, Cleare was a member of the board of directors of the Canadian biotechnology company, AnorMed, which he helped to spin off from Johnson Matthey in 1996, until its acquisition by Genzyme in 2006.
Cleare holds a B.Sc. and a M.S. from Imperial College in London and a Ph.D. from London University, where he worked in the laboratories of Nobel Laureate Sir Geoffrey Wilkinson. He has published over 40 scientific papers, many in peer reviewed journals, and is a named inventor on over 10 patents, including the fundamental composition patent for carboplatin.